#######################
# Document Properties #
#######################

SET DOCUMENT Licenses    = "MIT License"
SET DOCUMENT ContactInfo = "farah.humayun@scai-extern.fraunhofer.de"

SET DOCUMENT Name        = "heme_25307023.bel"
SET DOCUMENT Version     = "1.0.0"
SET DOCUMENT Authors     = "Farah Humayun"
SET DOCUMENT Description = "Heme BEL model is a disease model based on Biological Expression Language (BEL) containing the core mechanisms of heme as modulator in Hemolytic diseases such as sickle-cell anemia, beta-thalassemia, malaria and autoimmune hemolytic anemia."

##############
# Namespaces #
##############

# Namespaces hosted on https://github.com/pharmacome/terminology
# --------------------------------------------------------------
DEFINE NAMESPACE CHEBI          AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/chebi-names.belns"
DEFINE NAMESPACE DRUGBANK       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/drugbank-names.belns"
DEFINE NAMESPACE ECCODE         AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/ec-code.belns"
# DEFINE NAMESPACE FB           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/80171ae62cf43aa1fc8a6c326b94537ab342458c/external/fb-names.belns"
DEFINE NAMESPACE HBP            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/export/hbp-names.belns"
DEFINE NAMESPACE HGNC           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/hgnc-names.belns"
DEFINE NAMESPACE HGNCGENEFAMILY AS URL "https://raw.githubusercontent.com/pharmacome/terminology/3074b85b858455d8eeb76cfcdef685ced19bbe11/external/hgnc.genefamily-names.belns"
DEFINE NAMESPACE GO             AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/go-names.belns"
DEFINE NAMESPACE INTERPRO       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/interpro-names.belns"
DEFINE NAMESPACE MESH           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/01c9daa61012b37dd0a1bc962521ba51a15b38f1/external/mesh-names.belns"
DEFINE NAMESPACE MGI            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/mgi-names.belns"
DEFINE NAMESPACE MIRBASE        AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/mirbase-names.belns"
DEFINE NAMESPACE NCBIGENE       AS URL "https://raw.githubusercontent.com/pharmacome/terminology/b46b65c3da259b6e86026514dfececab7c22a11b/external/entrez.belns"
DEFINE NAMESPACE PFAM           AS URL "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns"
DEFINE NAMESPACE RGD            AS URL "https://raw.githubusercontent.com/pharmacome/terminology/f2f993e599694ab5ce989cc39d789a499f75db99/external/rgd-names.belns"

# Namespaces hosted on https://github.com/sorgerlab/famplex
# ---------------------------------------------------------
DEFINE NAMESPACE FPLX           AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns"

# Namespaces hosted on https://arty.scai.fraunhofer.de/artifactory/bel/namespace
# ------------------------------------------------------------------------------
DEFINE NAMESPACE CTO            AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/clinical-trial-ontology/clinical-trial-ontology-1.0.0.belns"
DEFINE NAMESPACE DO             AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20170725.belns"
DEFINE NAMESPACE HP             AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hp/hp-20171108.belns"
DEFINE NAMESPACE SCOMP          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-named-complexes/selventa-named-complexes-20170725.belns"
DEFINE NAMESPACE SFAM           AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/selventa-protein-families/selventa-protein-families-20170725.belns"

# Namespaces defined with regular expressions
# -------------------------------------------
DEFINE NAMESPACE DBSNP          AS PATTERN "rs[0-9]+"
DEFINE NAMESPACE TAXONOMY       AS PATTERN "^\d+$"
DEFINE NAMESPACE UNIPROT        AS PATTERN "^([A-N,R-Z][0-9]([A-Z][A-Z, 0-9][A-Z, 0-9][0-9]){1,2})|([O,P,Q][0-9][A-Z, 0-9][A-Z, 0-9][A-Z, 0-9][0-9])(\.\d+)?$"
DEFINE NAMESPACE PUBCHEM        AS PATTERN "^\d+$"

DEFINE NAMESPACE HM        AS PATTERN ".*"

###############
# Annotations #
###############

# Annotations defined with regular expressions
# --------------------------------------------

DEFINE ANNOTATION Species       AS PATTERN ".*"
DEFINE ANNOTATION TimePoint     AS PATTERN ".*"
DEFINE ANNOTATION Concentration     AS PATTERN ".*"

# Annotations hosted on https://arty.scai.fraunhofer.de/artifactory/bel/annotation
# --------------------------------------------------------------------------------
DEFINE ANNOTATION Anatomy       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/anatomy/anatomy-20170511.belanno"
DEFINE ANNOTATION CellLine      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno"
DEFINE ANNOTATION CellStructure AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno"
DEFINE ANNOTATION Cell          AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell/cell-20170511.belanno"
DEFINE ANNOTATION Confidence    AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/confidence/confidence-1.0.0.belanno"
DEFINE ANNOTATION Disease       AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/disease/disease-20170511.belanno"
DEFINE ANNOTATION Gender        AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/gender/gender-1.0.0.belanno"
DEFINE ANNOTATION MeSHAnatomy   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno"
DEFINE ANNOTATION MeSHDisease   AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
DEFINE ANNOTATION Subgraph      AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/neurommsig/neurommsig-1.0.3.belanno"
DEFINE ANNOTATION TextLocation  AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/text-location/text-location-1.0.1.belanno"

##############
# Statements #
##############

SET Citation = {"PubMed", "Br J Haematol. 2015 Jan;168(2):175-85. doi: 10.1111/bjh.13183. Epub 2014 Oct 13.", "25307023"}

SET TextLocation = "Review"

SET Evidence = "The triad consists
of hypercoagulability, blood stasis and endothelial injury/dysfunction,
which are useful concepts for understanding
thrombosis."

path(HP:Hypercoagulability) pos path(MESH:Thrombosis)
bp(MESH:Hemostasis) pos path(MESH:Thrombosis)
path(HM:"Endothelial dysfunction") pos path(MESH:Thrombosis)

SET Evidence = "Haemolysis, which is observed in multiple diseases,
can affect all three components of Virchow’s triad;
thus, it is not surprising that there is a link between haemolytic
disorders and thrombosis."

path(MESH:Hemolysis) -- path(MESH:Thrombosis)

SET Evidence = "The essential feature of any haemolytic disorder is shortened
red blood cell (RBC) lifespan."

path(MESH:Hemolysis) neg bp(MESH:"Erythrocyte Count")

SET Evidence = "The haptoglobin–haemoglobin complex is
recognized by the haemoglobin scavenger receptor, CD163,
on the surface of monocytes/macrophages, which mediates
haptoglobin–haemoglobin endocytosis and degradation (Kristiansen
et al, 2001)."

SET Cell = "macrophage"
p(HGNC:CD163) -> deg(a(MESH:"haptoglobin-hemoglobin complex"))

SET Evidence = "Formation of large amounts of haptoglobin–
haemoglobin complexes rapidly depletes haptoglobin."

a(MESH:"haptoglobin-hemoglobin complex") -| p(HGNC:HP)

SET Evidence = "Thus, in severe haemolytic diseases, such as paroxysmal nocturnal
haemoglobinuria (PNH) and sickle cell disease (SCD),
serum haptoglobin is typically undetectable and plasma
haemoglobin is elevated (Tabbara, 1992)."

path(HP:"Paroxysmal nocturnal hemoglobinuria") -| p(HGNC:HP)
path(HP:"Paroxysmal nocturnal hemoglobinuria") -> p(HGNC:HBB)
path(MESH:"Anemia, Sickle Cell") -| p(HGNC:HP)
path(MESH:"Anemia, Sickle Cell") -> p(HGNC:HBB)

SET Evidence = "Ferrous (Fe2+) haem, the oxygen-binding component of
haemoglobin, can be oxidized to ferric (Fe3+) haem (thereby
producing methaemoglobin), which is then released from
haemoglobin and binds with high affinity to circulating haemopexin
(Hvidberg et al, 2005)."

complex(a(CHEBI:methemoglobin), p(HGNC:HPX))

SET Evidence = "Normally, haemopexin
safely transports haem away from the vessel wall to ligate
LRP1 (also termed CD91) on hepatocytes and macrophages,
where the haem–haemopexin complex is endocytosed and
haem is degraded intracellularly (Hvidberg et al, 2005)."

SET Cell = "macrophage"
p(HGNC:LRP1) -> deg(complex(a(CHEBI:heme), p(HGNC:HPX)))
p(HGNC:LRP1) -> deg(a(CHEBI:heme))

SET Evidence = "Carbon monoxide has
vasodilatory, anti-proliferative, anti-inflammatory and antioxidant
properties, whereas bilirubin, the product of biliverdin
reductase, is an antioxidant (Baranano et al, 2002)."

a(CHEBI:"carbon monoxide") -> bp(MESH:Vasodilation)
a(CHEBI:"carbon monoxide") -| bp(GO:"cell proliferation")
a(CHEBI:"carbon monoxide") -| path(MESH:Inflammation)
a(CHEBI:"carbon monoxide") pos act(a(CHEBI:antioxidant))
a(CHEBI:bilirubin) pos act(a(CHEBI:antioxidant))

SET Evidence  = "Thus,
the antioxidant, anticoagulant, anti-proliferative and vasodilating
effects of the HMOX1 and biliverdin reductase systems
probably compensate for the nitric oxide (NO) scavenging,
vasoconstrictive, proliferative, inflammatory and pro-oxidant
effects of circulating free haemoglobin, haem and haem-iron,
which are discussed below (Rother et al, 2005)."

p(HGNC:HBB) -| bp(MESH:Vasodilation)
p(HGNC:HBB) -> bp(GO:"cell proliferation")
p(HGNC:HBB) -> path(MESH:Inflammation)
p(HGNC:HBB) -| act(a(CHEBI:antioxidant))
a(CHEBI:heme) -| bp(MESH:Vasodilation)
a(CHEBI:heme) -> bp(GO:"cell proliferation")
a(CHEBI:heme) -> path(MESH:Inflammation)
a(CHEBI:heme) neg act(a(CHEBI:antioxidant))
a(CHEBI:"iron(2+)") -| bp(MESH:Vasodilation)
a(CHEBI:"iron(2+)") -> bp(GO:"cell proliferation")
a(CHEBI:"iron(2+)") -> path(MESH:Inflammation)
a(CHEBI:"iron(2+)") -| act(a(CHEBI:antioxidant))

SET Evidence = "Haemoglobin and haem levels increase in plasma and
urine when haptoglobin and haemopexin scavenging mechanisms
are saturated during acute or chronic haemolysis."

SET MeSHAnatomy = {"Plasma", "Urine"}
path(MESH:Hemolysis) pos p(HGNC:HBB)
path(MESH:Hemolysis) pos a(CHEBI:heme)

SET Evidence = "Free plasma haemoglobin and haem also scavenge NO and
have multiple pro-inflammatory and pro-oxidant properties
that mediate many of the adverse effects of haemolysis."

p(HGNC:HBB) -| a(CHEBI:"nitric oxide")
a(CHEBI:heme) -| a(CHEBI:"nitric oxide")
p(HGNC:HBB) -> path(MESH:Inflammation)
a(CHEBI:heme) -> path(MESH:Inflammation)
p(HGNC:HBB) -| act(a(CHEBI:antioxidant))
a(CHEBI:heme) -| act(a(CHEBI:antioxidant))

SET Evidence = "Multiple haemolytic disorders and therapeutic interventions
produce substantial intravascular haemolysis. Examples
include PNH, SCD, thalassaemias, glucose-6-phosphate dehydrogenase
(G6PD) deficiency, hereditary spherocytosis and
stomatocytosis, pyruvate kinase deficiency, autoimmune haemolytic
anaemia, microangiopathies, acute haemolytic
transfusion reactions, mechanical circulatory support
[e.g., left ventricular assist device (LVAD)/extracorporeal
membrane oxygenation (ECMO)], RBC transfusions and
infusions of RBC substitutes. These disorders, therapies and
procedures are also associated with an increased risk of
thrombosis."

path(HP:"Paroxysmal nocturnal hemoglobinuria") -> path(MESH:Hemolysis)
path(MESH:"Anemia, Sickle Cell") -> path(MESH:Hemolysis)
path(MESH:Thalassemia) -> path(MESH:Hemolysis)
a(HM:"Glucose-6-phosphate dehydrogenase deficiency") -> path(MESH:Hemolysis)
path(MESH:"Spherocytosis, Hereditary") -> path(MESH:Hemolysis)
path(HP:Stomatocytosis) -> path(MESH:Hemolysis)
path(MESH:"Pyruvate Kinase Deficiency of Red Cells") -> path(MESH:Hemolysis)
path(HP:"autoimmune hemolytic anemia") -> path(MESH:Hemolysis)
path(MESH:"Thrombotic Microangiopathies") -> path(MESH:Hemolysis)
a(MESH:"Blood Transfusion") -> path(MESH:Hemolysis)
#: infusion of red blood cells
a(MESH:"Blood Substitutes") -> path(MESH:Hemolysis)
path(HP:"Paroxysmal nocturnal hemoglobinuria") -- path(MESH:Thrombosis)
path(MESH:"Anemia, Sickle Cell") -- path(MESH:Thrombosis)
path(MESH:Thalassemia) -- path(MESH:Thrombosis)
a(HM:"Glucose-6-phosphate dehydrogenase deficiency") -- path(MESH:Thrombosis)
path(MESH:"Spherocytosis, Hereditary") -- path(MESH:Thrombosis)
path(HP:Stomatocytosis) -- path(MESH:Thrombosis)
path(MESH:"Pyruvate Kinase Deficiency of Red Cells") -- path(MESH:Thrombosis)
path(HP:"autoimmune hemolytic anemia") -- path(MESH:Thrombosis)
path(MESH:"Thrombotic Microangiopathies") -- path(MESH:Thrombosis)
a(HM:"acute hemolytic transfusion reaction") -- path(MESH:Thrombosis)
a(MESH:"Blood Transfusion") -- path(MESH:Thrombosis)
a(MESH:"Blood Substitutes") -- path(MESH:Thrombosis)

SET Evidence = "In PNH, uncontrolled complement activity leads to systemic
complications, principally through intravascular haemolysis
and platelet activation."

path(HP:"Paroxysmal nocturnal hemoglobinuria") -> bp(GO:"complement activation")
path(HP:"Paroxysmal nocturnal hemoglobinuria") -> path(MESH:Hemolysis)
path(HP:"Paroxysmal nocturnal hemoglobinuria") -> bp(MESH:"Platelet Activation")

SET Evidence = "Thromboembolism is the
most common cause of death in PNH patients and accounts
for 40–67% of deaths for which the cause is known."

SET MeSHDisease = "Hemoglobinuria, Paroxysmal"
path(MESH:Thromboembolism) pos path(MESH:Death)

SET Evidence = "SCD is a haemolytic disorder caused by a HBB (b-globin
gene) mutation leading to polymerization of haemoglobin S,
sickling, and haemolysis."

path(MESH:"Anemia, Sickle Cell") pos path(MESH:Hemolysis)

SET Evidence = "The abnormal phospholipid membrane
asymmetry present in the RBCs of b-thalassaemia and
SCD patients, with resultant phosphatidylserine exposure,
appears to play a significant role in the aetiology of the
observed hypercoagulable state and in the link between
haemolysis and thrombosis (Ataga et al, 2007)."

SET MeSHDisease = {"beta-Thalassemia", "Anemia, Sickle Cell"}
SET Cell = "erythrocyte"
a(CHEBI:"phosphatidyl-L-serine") pos path(HP:Hypercoagulability)
a(CHEBI:"phosphatidyl-L-serine") -> path(MESH:Hemolysis)
a(CHEBI:"phosphatidyl-L-serine") -> path(MESH:Thrombosis)

SET Evidence = "Although
RBC transfusions reduce the risk of stroke in SCD (Adams
et al, 1998), both clinical strokes and silent infarcts still
occur."

SET MeSHDisease = "Anemia, Sickle Cell"
a(MESH:"Blood Transfusion") neg path(MESH:Stroke)

SET Evidence = "Thrombotic events also occur in
b-thalassaemia patients; for example, pulmonary embolism,
portal vein thrombosis and deep vein thrombosis occurred in
29% of b-thalassaemia intermedia patients followed for
10 years (Cappellini et al, 2000)."

SET MeSHDisease = "beta-Thalassemia"
path(MESH:"beta-Thalassemia") pos path(MESH:"Pulmonary Embolism")
path(MESH:"beta-Thalassemia") pos path(HP:"Deep venous thrombosis") 
path(MESH:"beta-Thalassemia") pos path(HP:"Portal vein thrombosis")

SET Evidence = "The highest
prevalence was observed in splenectomized patients."

a(MESH:Splenectomy) pos path(MESH:Thrombosis)

SET Evidence = "The increased risk of thrombosis in patients who undergo
a splenectomy is important. About 22 000 splenectomies are
still conducted annually for all causes in the United States
and splenectomized patients have a 22-fold increased rate of
being hospitalized for deep vein thrombosis or pulmonary
embolism (Kristinsson et al, 2014)."

a(MESH:Splenectomy) pos path(MESH:"Pulmonary Embolism")
a(MESH:Splenectomy) pos path(HP:"Deep venous thrombosis") 

SET Evidence = "In a report of 28 heterogeneous patients
with either warm or cold AIHA, 5 of 15 episodes of haemolysis
were associated with venous thromboembolism (Hendrick,
2003)."

path(HP:"autoimmune hemolytic anemia") pos path(MESH:"Venous Thromboembolism")

SET Evidence = "In addition, 8 of 30 patients (27%) with
unspecified warm or cold AIHA experienced an episode of
venous thromboembolism (Pullarkat et al, 2002); of these,
the presence of a lupus anticoagulant identified AIHA
patients at higher risk for venous thromboembolism."

SET MeSHDisease = "Anemia, Hemolytic, Autoimmune"
a(MESH:"Lupus Coagulation Inhibitor") pos path(MESH:"Venous Thromboembolism")

SET Evidence = "This common X-linked inherited disorder, characterized by
severe intravascular and extravascular haemolysis, is classically
triggered by fava bean ingestion or pro-oxidant medications.
It causes haemolysis in susceptible individuals and an
association with thrombosis was described in multiple case
reports (Jewett, 1976; Thompson et al, 2013; Albertsen et al,
2014)."

a(HM:"Glucose-6-phosphate dehydrogenase deficiency") pos path(MESH:Hemolysis)
a(HM:"Glucose-6-phosphate dehydrogenase deficiency") pos path(MESH:Thrombosis)

SET Evidence = "Patients with hereditary haemolytic anaemia due to RBC
structural abnormalities have an increased risk of thromboembolic
events, particularly in splenectomized patients (Stewart
et al, 1996; Schilling et al, 2008)."

path(HP:"Congenital hemolytic anemia") pos path(MESH:Thromboembolism)

SET Evidence = "Although haemolysis and thrombosis are hallmarks of the
thrombo microangiopathies, such as disseminated intravascular
coagulation (DIC) and thrombotic thrombocytopenic
purpura/haemolytic uraemic syndrome (TTP/HUS), it is difficult
to isolate the causative role of haemolysis in the pathophysiology
of thrombosis in these complex disorders."

path(MESH:Hemolysis) pos path(MESH:"Thrombotic Microangiopathies")
path(MESH:Thrombosis) pos path(MESH:"Thrombotic Microangiopathies")
path(MESH:Hemolysis) pos path(MESH:"Disseminated Intravascular Coagulation")
path(MESH:Thrombosis) pos path(MESH:"Disseminated Intravascular Coagulation")
path(MESH:Hemolysis) pos path(HP:"Hemolytic-uremic syndrome")
path(MESH:Thrombosis) pos path(HP:"Hemolytic-uremic syndrome")

SET Evidence = "Immunological incompatibility of transfused RBCs can lead
to acute haemolytic transfusion reactions."

a(HM:"ABO-incompatible erythrocytes") pos path(MESH:"Transfusion Reaction")

SET Evidence  = "Although acute
intravascular haemolysis is a rare complication of transfusion,
it is among the most feared transfusion-associated complications,
principally because death may rapidly ensue."

path(MESH:"Transfusion Reaction") pos path(MESH:Death)

SET Evidence = "Surprisingly, 66% (187/282) of ABO incompatible transfusions
are asymptomatic; however, 67% (19/282) result in
death and 27% (76/282) in major morbidities (Bolton-Maggs
et al, 2014), including DIC (Goldfinger, 1977)."

a(HM:"ABO-incompatible erythrocytes") pos path(MESH:Death)
a(HM:"ABO-incompatible erythrocytes") pos path(MESH:"Disseminated Intravascular Coagulation")

SET Evidence = "Biochemical
and biomechanical changes occur in the RBCs during the
storage process, ultimately leading to increased haemolysis
upon transfusion (Cohen & Matot, 2013)."

a(MESH:"Blood Transfusion") -> path(MESH:Hemolysis)

SET Evidence = "Furthermore,
retrospective studies suggest an association between transfusion
of older, stored RBCs and thrombosis (Spinella et al,
2009)."

a(HM:"stored erythrocytes") -- path(MESH:Thrombosis)

SET Evidence = "For example, infusion of haem into humans is
associated with disturbances in coagulation assays and
overt thrombophlebitis (Simionatto et al, 1988)."

a(CHEBI:heme) -- path(MESH:"Blood Coagulation Disorders")
a(CHEBI:heme) -- path(HP:Thrombophlebitis)

SET Evidence = "The main mediator of these adverse 
effects is thought to be free haem
via its effects on NO scavenging, pro-inflammatory cytokine
responses, and reactive oxygen species (ROS) generation."

a(CHEBI:heme) neg a(CHEBI:"nitric oxide")
a(CHEBI:heme) pos a(MESH:"Reactive Oxygen Species")

SET Evidence = "NO is also known as endothelial-
derived relaxing factor, because of its role in signalling
to relax the smooth muscle lining the vasculature (Rother
et al, 2005)."

a(CHEBI:"nitric oxide") -> bp(GO:"relaxation of smooth muscle")

SET Evidence = "As such, it nitrosylates the haem-moiety of
guanylate cyclase, thereby stimulating formation of cyclic
guanine monophosphate (cGMP), which then initiates 
calcium-dependent vasodilation (Olson et al, 2004)."

a(CHEBI:"nitric oxide") -> a(CHEBI:"3',5'-cyclic GMP")
a(CHEBI:"3',5'-cyclic GMP") -> bp(GO:vasodilation)
bp(GO:"nitric oxide-cGMP-mediated signaling pathway") -> bp(GO:vasodilation)

SET Evidence = "During
intravascular haemolysis, NO availability is severely limited
by its reaction with oxyhaemoglobin (i.e., NO scavenging)
and by breakdown of the substrate for NO synthesis, L-arginine,
by arginase released from RBCs (Schnog et al, 2004)."

path(MESH:Hemolysis) -| a(CHEBI:"nitric oxide")

SET Evidence = "Oxyhaemoglobin reacts in a rapid and irreversible dioxygenation
reaction with NO to form methaemoglobin and nitrate
(Rother et al, 2005)."

rxn(reactants(a(CHEBI:oxyhemoglobin), a(CHEBI:"nitric oxide")), products(a(CHEBI:methemoglobin), a(CHEBI:nitrate)))

SET Evidence = "Thus, haemolysis results in NO scavenging,
systemic vasoconstriction and increased blood stasis,
thereby affecting one of the principle components of Virchow’s
Triad."

path(MESH:Hemolysis) pos bp(GO:vasoconstriction)
path(MESH:Hemolysis) pos bp(MESH:Hemostasis)

SET Evidence = "Furthermore, NO has a fundamental role in
normal vascular physiology by inhibiting both platelet aggregation
and endothelial adhesion molecule expression, as
detailed below"

a(CHEBI:"nitric oxide") -| path(MESH:"Platelet Aggregation")
a(CHEBI:"nitric oxide") -| a(MESH:"Cell Adhesion Molecules")

SET Evidence = "Finally, NO may also affect coagulation by
inhibiting Factor XIII activity (Catani et al, 1998)."

a(CHEBI:"nitric oxide") -| act(complex(p(HGNC:F13A1), p(HGNC:F13B)))

SET Evidence = "Factor
XIII stabilizes clots by catalysing fibrin monomer cross-linking;
thus, NO deficiency enhances clot stability and reduces
clot dissolution."

complex(p(HGNC:F13A1), p(HGNC:F13B)) -> a(HM:"fibrin monomer cross-linking")
complex(p(HGNC:F13A1), p(HGNC:F13B)) -| path(MESH:"Clot Retraction")
a(CHEBI:"nitric oxide") -> path(MESH:"Clot Retraction")

SET Evidence = "Therefore, decreased NO bioavailability
affects vascular tone, platelet and endothelial function and
coagulation, thus increasing thrombotic risk."

a(CHEBI:"nitric oxide") -| path(MESH:Thrombosis)

SET Evidence = "The large amounts of haem released upon haemolysis can
overwhelm the capacity of haem scavengers and enzyme systems
(i.e., HMOX1), thus causing oxidative stress (Jeney
et al, 2002)."

a(CHEBI:heme) -> bp(MESH:"Oxidative Stress")

SET Evidence = "ROS generation by haem is at least
partially dependent on the Fenton reaction, in which iron
catalyses the production of toxic ROS (Wagener et al, 2003)."

a(CHEBI:"iron(2+)") -> a(MESH:"Reactive Oxygen Species")

SET Evidence = "These ROS then
oxidize cell membrane constituents to induce cytotoxicity
and promote inflammation and thrombosis."

a(MESH:"Reactive Oxygen Species") -> bp(MESH:"Cytotoxicity, Immunologic")
a(MESH:"Reactive Oxygen Species") -> path(MESH:Inflammation)
a(MESH:"Reactive Oxygen Species") -> path(MESH:Thrombosis)

SET Evidence = "Furthermore, ROS induction by haem directly depends on
signal transduction involving Ga inhibitory protein and
phosphoinositide 3-kinase, and partially depends on phospholipase
Cb, protein kinase C, the mitogen-activated protein
kinases (MAPKs) and Rho kinase in neutrophils (Porto
et al, 2007)."

act(p(HGNC:PDPK1)) pos a(MESH:"Reactive Oxygen Species")
a(MESH:"Phospholipase C beta") pos a(MESH:"Reactive Oxygen Species")
a(MESH:"Protein Kinase C") pos a(MESH:"Reactive Oxygen Species")
a(MESH:"Mitogen-Activated Protein Kinases") pos a(MESH:"Reactive Oxygen Species")
p(HGNC:ROCK1) pos a(MESH:"Reactive Oxygen Species")

SET Evidence = "Transfusion of RBCs after prolonged refrigerator storage is
associated with haemolysis (Donadee et al, 2011; Hod et al,
2011) and enhances cytokine secretion in response to lipopolysaccharide
(LPS) administration (Hod et al, 2010)."

a(CHEBI:"lipopolysaccharide") -> a(MESH:Cytokines)

SET Evidence = "Haem increases lethality and cytokine secretion
induced by LPS in vivo and enhances cytokine secretion by
macrophages stimulated with various innate immune receptor
agonists (e.g., TLR2, TLR9, TLR3, and nucleotide-binding
oligomerization domain (NOD) agonists) (Fernandez et al,
2010)."

SET Cell = "macrophage"
p(HGNC:TLR2) -> a(MESH:Cytokines)
p(HGNC:TLR9) -> a(MESH:Cytokines)
p(HGNC:TLR3) -> a(MESH:Cytokines)
p(HGNC:NOD1) -> a(MESH:Cytokines)

SET Evidence = "Haem also induces tumour necrosis factor (TNF)
secretion in monocyte/macrophages through TLR4 and the
adaptor molecule, MYD88 (Figueiredo et al, 2007)."

SET Cell = "macrophage"
a(CHEBI:heme) -> p(HGNC:TNF)
p(HGNC:TLR4) -> p(HGNC:TNF)
p(HGNC:MYD88) -> p(HGNC:TNF)

SET Evidence = "Furthermore, cytokine secretion depends on the
coordinated iron in the porphyrin ring (Figueiredo et al,
2007), and nuclear factor-jB (NF-jB), MAPKs activation
and ROS are essential for the increase in cytokine production
induced by haem (Fernandez et al, 2010)."

a(CHEBI:"iron coordination entity") pos a(MESH:Cytokines)
p(HGNC:NFKB1) -> a(MESH:Cytokines)
p(HGNC:MAPK1) -> a(MESH:Cytokines)
a(MESH:"Reactive Oxygen Species") pos a(MESH:Cytokines)

SET Evidence = "Finally, the cytokines
produced through these pathways can then affect endothelial
activation, leucocyte recruitment, and ultimately
thrombotic risk."

a(MESH:Cytokines) -- bp(GO:"endothelial cell activation")
a(MESH:Cytokines) -> path(MESH:Thrombosis)

SET Evidence = "Platelets may be activated during haemolysis by several different
mechanisms involving decreased NO levels, increased
pro-inflammatory cytokines and mediators, and ROS."

a(MESH:Cytokines) -> bp(MESH:"Platelet Activation")
a(CHEBI:"nitric oxide") -| bp(MESH:"Platelet Activation")
a(MESH:"Reactive Oxygen Species") ->  bp(MESH:"Platelet Activation")

SET Evidence = "NO inhibits platelet aggregation mediated by guanylate cyclase
activation with a subsequent rise in cGMP (Faint et al,
1991)."

a(CHEBI:"3',5'-cyclic GMP") -| bp(MESH:"Platelet Aggregation")

SET Evidence = "Platelet deposition and adhesion at sites of subintimal
injury are increased by free haemoglobin or inhibition of NO
production; this effect can be prevented by infusions of
L-arginine, the precursor of NO (Olsen et al, 1996)."

a(CHEBI:heme) -> bp(MESH:"Platelet Aggregation")
a(CHEBI:"nitric oxide") -| bp(MESH:"Platelet Aggregation")
a(CHEBI:"L-arginine") -| bp(MESH:"Platelet Aggregation")

SET Evidence = "In addition,
reduced NO bioavailability induces platelet activation
and aggregation, leading to thrombosis in a mouse model of
intravascular haemolysis (Hu et al, 2010)."
 
bp(MESH:"Platelet Aggregation") pos path(MESH:Thrombosis)
bp(MESH:"Platelet Activation") pos path(MESH:Thrombosis)

SET Evidence = "In patients with SCD (Wun et al, 1998) and b-thalassaemia
(Ruf et al, 1997), flow cytometry demonstrates the presence
of an increased fraction of platelets expressing P-selectin, a
platelet membrane receptor that mediates platelet–endothelial
interactions."

p(HGNC:SELP) pos bp(MESH:"Platelet Aggregation")

SET Evidence = "In addition, platelet-derived soluble CD40
ligand (CD40LG) is elevated in SCD patients, as compared
with normal controls (Lee et al, 2006). This inflammatory
ligand enhances adhesion molecule expression, stimulates
cytokine secretion and initiates coagulation (Lee et al, 2006)."

SET Evidence = "Furthermore,
haem-induced release of P-selectin and 
VWF is mediated by TLR4 and NFkB signalling."

SET Cell = "endothelial cell"
a(CHEBI:heme) -> p(HGNC:SELP)

SET MeSHDisease = "Anemia, Hemolytic, Autoimmune"
p(HGNC:CD40LG) -> a(MESH:"Cell Adhesion Molecules")
p(HGNC:CD40LG) -> a(MESH:Cytokines)
p(HGNC:CD40LG) -> path(MESH:"Blood Coagulation")

SET Evidence = "ADP induces platelet activation and may also contribute
to transfusion-related vascular thrombosis."

a(MESH:"Adenosine Diphosphate") pos bp(MESH:"Platelet Activation")

SET Evidence = "ADP released
from haemolysed RBCs induces CD40LG release from platelets
and lymphocytes, thereby contributing to the pro-inflammatory
and pro-thrombotic environment (Helms et al,
2013)."

a(MESH:"Adenosine Diphosphate") -> p(HGNC:CD40LG)
a(MESH:"Adenosine Diphosphate") pos path(MESH:Inflammation)
a(MESH:"Adenosine Diphosphate") pos path(MESH:Thrombosis)

SET Evidence = "Finally, ferrous iron, through Fenton-derived hydroxyl
radical species production and protein kinase C function,
activates platelets (Iuliano et al, 1994). "

a(CHEBI:"iron(2+)") -> bp(MESH:"Platelet Activation")

SET Evidence = "Thus, by participating
in Fenton chemistry, non-transferrin-bound iron (i.e., iron
not bound to the physiological iron transport protein, transferrin)
causes oxidative damage, cytotoxicity and enhanced
endothelial expression of adhesion molecules, thereby
enhancing thrombotic risk (Hershko, 2007)."

a(CHEBI:"iron(2+)") pos bp(MESH:"Oxidative Stress")
a(CHEBI:"iron(2+)") pos bp(MESH:"Cytotoxicity, Immunologic")
a(CHEBI:"iron(2+)") -> a(MESH:"Cell Adhesion Molecules")
a(CHEBI:"iron(2+)") -> path(MESH:Thrombosis)

SET Evidence = "For example, haem stimulates expression of P-selectin and
von Willebrand Factor (VWF) ‘strings’ on endothelial cells
in vitro and on the vessel walls of both normal and SCD
mice (Belcher et al, 2014)."

a(CHEBI:heme) -> p(HGNC:SELP)
a(CHEBI:heme) -> p(HGNC:VWF)

SET Evidence = "Inhibiting NADPH oxidase, its upstream activator
protein kinase C or antioxidants inhibit haem-mediated
stasis, Weibel-Palade body degranulation and oxidant
production by the endothelium (Belcher et al, 2014)."

a(MESH:"NADPH Oxidase") -> bp(MESH:Hemostasis)
a(MESH:"Protein Kinase C") -> bp(MESH:Hemostasis)
a(MESH:"NADPH Oxidase") -> a(HM:"Weibel Palade body degranulation") 
a(MESH:"Protein Kinase C") -> a(HM:"Weibel Palade body degranulation") 

SET Evidence = "Furthermore,
incubating endothelial cells with haem induces tissue
factor, which can initiate coagulation (Setty et al, 2008)."

a(CHEBI:heme) -> p(HGNC:F3)
p(HGNC:F3) pos path(MESH:"Blood Coagulation")

SET Evidence = "In addition, haem activates endothelial cell expression of
intracellular adhesion molecule 1 (ICAM1), vascular cell
adhesion molecule (VCAM1), and E-selectin (Wagener et al,
1997)."

a(CHEBI:heme) -> p(HGNC:ICAM1)
a(CHEBI:heme) -> p(HGNC:VCAM1)
a(CHEBI:heme) -> p(HGNC:SELE)

SET Evidence = "Decreased
function of this zinc-containing metalloprotease that cleaves
VWF is implicated in the pathogenesis of both congenital and
sporadic TTP (Furlan et al, 1998)."

p(HGNC:ADAMTS13) neg path(MESH:"Purpura, Thrombotic Thrombocytopenic")

SET Evidence = "Pro-inflammatory cytokines and chemokines [e.g., inter
leukin 1B (IL1B), CXCL8 (also termed IL8), TNF and chemokine (C-C
motif) ligand 2 (CCL2, also termed MCP1)], are upregulated in 
haemolytic disorders such as SCD (Qari et al, 2012).
This pro-inflammatory cytokine milieu is crucial in mediating 
the pro-coagulant effects of vascular endothelial cells and 
promotes localized inflammation and thrombosis (Qari et al, 2012)."

p(HGNC:IL1B) -> path(MESH:Inflammation)
p(HGNC:IL1B) -> path(MESH:Thrombosis)
p(HGNC:CXCL8) -> path(MESH:Inflammation)
p(HGNC:CXCL8) -> path(MESH:Thrombosis)
p(HGNC:TNF) -> path(MESH:Inflammation)
p(HGNC:TNF) -> path(MESH:Thrombosis)
p(HGNC:CCL2) -> path(MESH:Inflammation)
p(HGNC:CCL2) -> path(MESH:Thrombosis)

SET Evidence = "Furthermore, haem released
during SCD-induced haemolysis triggers the release of neutrophil
extracellular traps (NETs) via a ROS-dependent
mechanism (Chen et al, 2014)."

path(MESH:Hemolysis) pos a(MESH:"Extracellular Traps")

SET Evidence = "Thus, NETs recruit RBCs, activate
platelets and promote fibrin deposition; they are a previously
unrecognized link between haemolysis and thrombosis
that may further explain this epidemiological association."

a(MESH:"Extracellular Traps") -> bp(MESH:"Platelet Activation")
a(MESH:"Extracellular Traps") -> a(HM:"fibrin deposition")

SET Evidence = "Furthermore, phosphatidylserine is
actively maintained on the inner leaflet of the bilayer membrane
and, when externalized, is a recognition signal for cell
clearance or for activation of coagulation (Zwaal & Schroit,
1997)."

a(CHEBI:"phosphatidyl-L-serine") pos path(MESH:"Blood Coagulation")

SET Evidence = "These RBC microparticles
can initiate and propogate thrombin generation
(Rubin et al, 2013)."

a(CHEBI:"phosphatidyl-L-serine") pos a(CHEBI:Thrombin)

UNSET TextLocation
################